Aristides Capital’s Editas Medicine EDIT Stock Holding History

Aristides Capital’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-131,900	Closed	-$168K	–	257
2024 Q4	$168K	Buy	+131,900	New	+$336K	0.03%	266

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Aristides Capital's EDIT Position: Q1 2025 in Review

Aristides Capital sold out of Editas Medicine (EDIT) in Q1 2025, closing a stake of 131,900 shares — an estimated $168K sold.

Aristides Capital first reported a position in EDIT in Q4 2024 and held it in 1 quarter. The position peaked at $168K in Q4 2024. 194 funds tracked by Wall St. Rank hold EDIT as of Q1 2025.

Aristides Capital reported no remaining Editas Medicine position as of Q1 2025 after selling out during the quarter.
Aristides Capital sold 131,900 Editas Medicine shares in Q1 2025, an estimated $168K.
Aristides Capital first reported a position in Editas Medicine in Q4 2024 and held it in 1 quarter.
Aristides Capital's Editas Medicine position peaked at $168K in Q4 2024.
194 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2025.

Based on Aristides Capital's 13F filing for Q1 2025, filed 14 May 2025.